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Abstract
Background: Motor neuron degeneration in SOD1
G93A transgenic mice begins at the nerve terminal. Here we examine
whether this degeneration depends on expression of mutant SOD1 in muscle fibers.
Methodology/Principal Findings: Hindlimb muscles were transplanted between wild-type and SOD1
G93A transgenic mice
and the innervation status of neuromuscular junctions (NMJs) was examined after 2 months. The results showed that
muscles from SOD1
G93A mice did not induce motor terminal degeneration in wildtype mice and that muscles from wildtype
mice did not prevent degeneration in SOD1
G93A transgenic mice. Control studies demonstrated that muscles transplanted
from SOD1
G93A mice continued to express mutant SOD1 protein. Experiments on wildtype mice established that the host
supplied terminal Schwann cells (TSCs) at the NMJs of transplanted muscles.
Conclusions/Significance: These results indicate that expression of the mutant protein in muscle is not needed to cause
motor terminal degeneration in SOD1
G93A transgenic mice and that a combination of motor terminals, motor axons and
Schwann cells, all of which express mutant protein may be sufficient.
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Introduction
The SOD1
G93A transgenic mouse is a common model for
studying motor neuron disease and ubiquitously expresses one
(G93A) of many SOD1 protein mutations known to occur in about
20% of human cases of inherited motor neuron disease [1].
Previous studies have shown that expression of the mutated
SOD1
G93A gene solely in neurons does not cause motor neuron
disease [2]. This and other evidence suggest that toxic interactions
between motor neurons and other cells all of which express the
mutant SOD1 protein may be important for disease progression
[3–5]. An important consideration is where to place emphasis in
the search for such interactions. Recent evidence indicates that
motor terminal degeneration in SOD1
G93A mice occurs long
before motoneuron cell death in the spinal cord [6–8]. This
evidence indicates that loss of motor unit function is the result of
degenerative events in the periphery and not motor neuron cell
death [9,10]. Similar phenomena were reported earlier in a canine
version of inherited motor neuron disease [11–13].
Motor neuron cellular partners that might contribute to motor
terminal degeneration include myelinating Schwann cells and, at
the neuromuscular junction (NMJ), muscle fibers and terminal
Schwann cells (TSC). The results of an earlier study in which
muscles were transplanted between SOD1
G93A and wild-type mice
suggested that muscle may exert a toxic influence in SOD1
G93A
mice [14]. Another study, however, reported that expression of
mutant SOD1 protein in muscle does not contribute to the
pathogenesis of SOD1
G93A mice [15]. The approach used in the
latter study was to inhibit expression of mutated SOD1 protein in
muscle but the results showed that the inhibition was not complete
and leave open the possibility that expression in some or many
muscle fibers may have been unaffected.
In order to clarify the role of muscle in determining motor
terminal degeneration in SOD1
G93A mice, we transplanted whole
muscles between SOD1
G93A and wild-type mice in the present
study. The results showed that mutant SOD1-expressing muscles
were not able to induce motor terminal degeneration in wildtype
animals and that wildtype SOD1-expressing muscles were unable
to prevent motor terminal degeneration in SOD1
G93A transgenic
mice. The results thus demonstrate that the properties of the host
animal and not the muscle transplant source determine whether
degenerative changes at the NMJ are subsequently observed. Since
the source of TSCs in transplanted adult muscles was not known
with certainty, we examined this issue using transgenic mice with
fluorescently-labeled TSCs [16]. Here we show that in the adult,
all TSCs in regenerated muscle transplants are derived from the
host. Our results indicate that pairings of SOD1-expressing
Schwann cells, motor terminals and motor axons are sufficient
to enable motor terminal degenerative changes in the SOD1
G93A
mouse and that interactions with mutant SOD1 expressing muscle
fibers do not play a role. Some of these results have been reported
previously in abstract form [17].
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9802Results
Wild-type motor neurons successfully innervate SOD1
MG transplants
In this study, SOD1 animals on a B6 background (B6.SOD1)
and wildtype B6 controls both possessed YFP-labeled axons to
facilitate imaging [18]. MG muscles from B6.SOD1 donors were
transplanted into wild-type hosts and recovered and analyzed for
innervation status 2 months later. Sections taken from these
muscles revealed the presence of many YFP-labeled axons that
extended throughout an endplate band to form synaptic contacts
on motor endplates labeled for acetylcholine (ACh) receptors with
a2bungarotoxin (Figure 1A). Although not analyzed, the number
of endplates in transplanted muscles appeared to be similar to
contralateral, control muscles, and similar numbers of endplates
were analyzed for innervation status (transplant 13368, contra-
lateral 14464, N=5 for both). The innervation status of muscle
fibers in transplanted muscles was compared with the innervation
status of the contralateral, control muscles by determining the
extent to which endplates labeled for ACh receptors were
occupied by synaptophysin-labeled nerve terminals. The results
showed that transplanted B6.SOD1 muscles featured similar
percentages of innervated and partially innervated muscle fibers
relative to contralateral MG muscles (Figure 1B). The relatively
small differences of innervation status were sufficient to produce a
statistically significant association between innervation status and
muscle source (transplant or control, p,0.01). The significance,
however, depended upon comparisons within 2 animals in which
the control muscles contained endplates that were 0% partially
innervated and denervated and transplant muscles that had small
but discrete percentages in these categories (5% on average or
less). Factors other than genotype likely play a role in determining
the small amounts of partial innervation and denervation in the
transplanted muscles. Even in transplants of completely normal
muscles, reinnervation is delayed by muscle fiber regeneration that
follows after elimination of necrotic fibers [19,20].
The results of several previous studies suggest that motor
neurons which innervate fast type motor units are more susceptible
to degeneration in SOD1
G93A mice [6,21]. If such an effect is
based on toxicity mediated by fast-type muscle fibers, then the
Figure 1. Wild-type motor neurons successfully reinnervate B6.SOD1 muscles. A. Low magnification view of an MG muscle from an
B6.SOD1mouse transplanted into a wild-type animal 2 months earlier. The host B6.SOD1 animal expressed YFP in neuronal membranes (green) while
ACHRs at endplates were labeled with a-bungarotoxin (a2Btx, red). The endplates in this view were all fully innervated by YFP-fluorescent motor
terminals as indicated by yellow color. B. Bar charts show percentages of fully and partially innervated endplates and denervated endplates for
transplanted and contralateral control MG muscles as determined by synaptophysin staining (not shown). Bar pairs correspond to the same animals.
C. Low magnification views of YFP-labeled motor terminals and synapses (column 1), views of muscle fibers stained with an antibody against fast
myosin (My32, column 2) and merged views (YFP, green) for sections taken from a transplanted MG muscle and a contralateral control MG from one
animal. These panels demonstrate that fast muscle fibers regenerated in transplanted B6.SOD1 MG and were as completely innervated in
transplanted B6.SOD1 MG muscle as in the contralateral MG muscle.
doi:10.1371/journal.pone.0009802.g001
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wild-type motoneurons could be based on a failure of fast-type
muscle fibers to regenerate in the transplanted muscles. However,
sections of transplanted B6.SOD1 MG muscles showed that many
innervated muscle fibers stained positively with an antibody for
fast myosin and in this respect, these fibers were similar to those
found in contralateral MG muscles (Figure 1C). In other sections
from transplanted and contralateral control muscles, fewer muscle
fibers were observed that did not stain positively for fast myosin
(data not shown), consistent with the presence of a minority (ca.
6%) of slow muscle fibers in the mouse MG muscle [22]. These
data demonstrate that B6.SOD1 MG muscles and motor
endplates regenerate after being transplanted into wild-type
animals and express different fiber types. Overall, wild-type motor
neurons and motor terminals were able to innervate the
transplanted B6.SOD1 MG muscles almost completely. Muscle
fibers from B6.SOD1 mice are thus able to receive and maintain
innervation from wild-type motor terminals.
Another explanation for the nearly complete innervation of
B6.SOD1 MG transplants by wild-type motor neurons is that the
regenerated fibers in transplants do not express the mutant SOD1
protein. Previous studies have shown, however, that adult muscles
retain transgene expression following transplantation into im-
munocompatible hosts [23]. In order to confirm this in the present
study, we performed Western analysis of SOD1 expression in MG
muscle from an B6.SOD1 donor that had been transplanted into a
wild-type host 2 months earlier. The results (Figure 2) confirm that
expression of the mutated SOD1 protein is maintained in muscles
transplanted from B6.SOD1 animals into wild-type animals.
Moreover, these data demonstrate that the source of the muscle
fibers in the transplant is the SOD1 donor animal
Wild-type MG transplants do not prevent B6.SOD1 motor
terminal degeneration
In another series of experiments, wild-type MG muscles were
transplanted into the legs of B6.SOD1 transgenic mice. In contrast
with the transplantation of B6.SOD1 muscle into wild-type
animals, an appreciable number of denervated and partially
occupied endplates were encountered in the transplanted MG
muscles (Figure 3A). The extent of NMJ abnormalities in the
transplanted muscles, however, was similar to contralateral
muscles. To quantify this observation, the innervations status of
transplanted and contralateral control muscles was evaluated as
described above. Two months after transplantation, we observed
that the average percentages of innervated, partially innervated
and denervated muscle fibers in the wild-type MG transplants did
not differ significantly from percentages obtained from control,
unoperated, MG muscles of B6.SOD1 mice (p.0.05, Figure 3B).
As was the case in B6.SOD1 muscles transplanted into wild-type
animals, the number of endplates in transplanted wildtype muscles
did not appear to differ from contralateral, control muscles, and
similar numbers were available for analysis (14469 for transplants,
12866 for control muscles, both N=5). In addition, fiber type
expression in wild-type MG muscles transplanted into B6.SOD1
animals was similar to contralateral MG muscles and was
dominated by staining for fast myosin (Figure 3C).
The overall lack of difference of innervation status between
transplanted and contralateral muscles could arise because some
fibers in the transplanted wild-type muscles never became
innervated. This possibility cannot be excluded since we did not
use repeated in vivo imaging of endplates in transplanted muscles
throughout the post-operative period. In one B6.SOD1 host
animal, however, the MG muscle on the side contralateral to the
transplant exhibited considerably less innervation than the
remainder of the group, but this was matched by a similarly low
percentage of fully innervated fibers on the transplanted side
compared with muscles from other transgenic animals (Figure 3B).
The overall side-to-side similarity of innervation status suggests
that motor terminals in the transplanted wild-type muscle are
subject to the same degeneration schedule as motor terminals on
the contralateral side. Combined with the fact that most fibers (ca.
65%) in the transplants were found to be innervated in 4/5
experiments, these results suggest that the transplants were
extensively innervated initially and that some fibers became
denervated only later.
Figure 4 summarizes innervation status and Table 1 provides
group means for all transplant experiments. For both types of
transplantexperiment,therewasanequivalenceofinnervationstatus
between transplant and contralateral control muscle pairs. This
observation indicates that innervation in transplanted and contra-
lateral control muscles is affected by a common factor The most
obvious common factor associated with transplanted and contralat-
eral muscle pairs is the identity of the host and not the identity of the
donor. This indicates that the properties of the transplant recipient
determine innervation status in both transplanted and contralateral
control muscles. By extension, this supports the conclusion that the
properties of transplanted muscles have no effect on innervation
status in either wild-type or B6.SOD1 transgenic mice.
Terminal Schwann cells are derived from the transplant
host
In addition to its relationship with the muscle fiber, the motor
terminal is intimately covered by the terminal Schwann cell (TSC).
Because of this close relationship, potentially toxic interactions
with TSCs could be a factor in determining or influencing motor
terminal degeneration in SOD1
G93A mice. The source of TSCs in
transplanted muscles is not clear, however. Previously, it has been
reported that only about half of TSCs are derived from the host
when neonatal whole muscles are transplanted [24]. In order to
determine the source of TSCs in the present experiments in adults,
we performed MG muscle transplants between wild-type mice and
transgenic mice that express EGFP under the direction of the
human S100 calcium-binding protein promoter [16]. Because
TSCs in these transgenic mice (B6.EGFP) are fluorescent, it is
possible determine the source of TSCs after transplantation.
Following a 2 month post-transplantation delay, we observed
that all the MG muscles transplanted from wild-type mice into the
B6.EGFP mice showed EGFP fluorescence at their NMJs
(Figure 5A). In contrast, none of the NMJs in MG muscles from
Figure 2. SOD1
G93A mutant protein is expressed in transplant-
ed muscles. Western blots showing reactivity of antibodies against
mouse SOD1 protein (aM-SOD1) and against human SOD1 protein (aH-
SOD1) which is used to label the human mutant SOD1 protein. Lanes
are as follows: 1. B6.SOD1 transgenic MG muscle; 2. Wild-type MG
muscle; 3. MG muscle from B6.SOD1 transgenic transplanted 2 months
earlier into a wild-type animal; 4. Control muscles were obtained from
the ipsilateral limb (soleus).
doi:10.1371/journal.pone.0009802.g002
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fluorescence (Figure 5B). In order to determine whether TSCs
were present but not EGFP fluorescent in the latter muscles, we
labeled muscle sections with an antibody against the S100 protein
and observed S100-positive staining at all nerve terminals
(Figure 5B). This demonstrates that TSCs were present at these
NMJs but did not contain the EGFP label. We also considered the
possibility that some wild-type TSCs might survive the transplan-
tation to B6.EGFP mice and express S100 but not EGFP.
However, we observed that every instance of S100-positive
staining co-localized with EGFP fluorescence (Figure 5C).
The co-localization of EGFP fluorescence and S100 staining at
nerve terminals of MG muscles transplanted from wild-type mice
into EGFP mice (Figure 5) indicates that all TSCs in the muscle
transplants are provided by the host. Additional evidence indicates
that donor TSCs do not survive the transplantation procedure. In
a preliminary experiment, no evidence was detected of EGFP
fluorescence or S100 antibody positive staining in an MG muscle
transplanted 2 weeks previously from a wild-type mouse into an
B6.EGFP mouse. However, both markers were present in the
contralateral unoperated MG which was denervated at the time of
the transplant surgery via ipsilateral sciatic nerve crush (data not
shown).
Discussion
One goal of the present study was to test the hypothesis that
expression of the mutant SOD1
G93A protein in muscle is necessary
Figure 3. B6.SOD1 motor neurons fail to completely reinnervate wild-type muscles. A1. Low magnification view of wild-type muscle
transplanted into an B6.SOD1 animal 2 months earlier. The host wildtype animal expressed YFP in neuronal membranes (green) while ACHRs are
labeled with a2Btx (red). Denervated endplates are indicated by white arrows. A2–3. Higher magnification and rotated view of area indicated in A1
by broken lines. Panels illustrate complete occupation of upper endplate by nerve terminal (A2, YFP) and synaptophysin staining (A3, SYP) and
complete denervation of lower endplate. B. Percentages of fully and partially innervated endplates and denervated endplates for transplanted and
contralateral control MG muscles. Bar pairs correspond to the same animals. C. Low magnification views of YFP-labeled motor terminals and My32–
stained muscle fibers show that fast muscle fibers regenerated in wild-type MG muscle transplanted into B6.SOD1 animals and showed similar levels
of denervation.
doi:10.1371/journal.pone.0009802.g003
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plish this, we used inbred mouse lines and transplanted muscles
from B6.SOD1 transgenic mice into wild-type mice and from
wild-type mice into B6.SOD1 transgenics. We found that NMJ
innervation status was essentially equivalent between transplant
and contralateral control muscle pairs in both types of transplant
experiments (Figure 4). Since muscle pairs have the host in
common, this association indicates that the properties of the host
and not the donor determine NMJ innervation status. Thus,
transplanted B6.SOD1 transgenic muscles successfully accept and
retain innervation from wild-type motor neurons. Motor neurons
in B6.SOD1 transgenic mice exhibit the same inability to either
make or retain innervation on regenerated wild-type muscle fibers
as do B6.SOD1 motor neurons innervating contralateral control
muscles. These results indicate that mutant protein expression in
muscle makes no contribution to denervation in SOD1 mice.
Using behavioral tests, Miller et al [15] reached a similar
conclusion after reducing expression of mutant protein in muscles
of mice that ubiquitously express SOD1
G93A. The reduction was
incomplete, however, leaving open the possibility that reduced
expression of mutant protein in muscle or a reduced number of
expressing fibers is sufficient to cause the motor neuron disease
phenotype. The observation that transplanted wild-type muscles
do not inhibit the occurrence of muscle denervation in B6.SOD1
mice provides increased confidence that expression of the G93A
SOD1 mutation in muscle is not necessary for the appearance of
muscle denervation or the motor neuron disease phenotype.
An alternative explanation for the ability of wild-type motor
neurons to innervate transplanted B6.SOD1 muscles is that the
muscles did not express the mutated protein. This possibility was
excluded by showing that B6.SOD1 muscle continues to express
the mutated enzyme 2 months after transplantation into wild-type
mice (Figure 2). This is consistent with the results of a previous
study in which muscles continued expressing a transgene following
transplantation into wild-type hosts [23]. The basis for these results
likely resides in the mechanisms underlying recovery and
regeneration following transplantation of whole muscles. Soon
after transplantation, muscle fibers become ischemic and most
appear to degenerate. Repopulation of muscle fibers is accom-
plished by activation and differentiation of satellite cells located
within the original basal lamina [20]. Others have shown that host
myoblasts do not invade transplanted muscles [24]. The source of
regenerated muscle fibers in whole muscle transplants thus appears
to be the transplanted muscle itself.
Another alternative idea is that MG motor terminal degeneration
in the SOD1-.Wt transplant group was absent because motor ter-
minals were exposed for only 60 days (post-transplant interval) to
SOD1 muscle. Although not identical, this time is comparable to the
time MG motor terminals were exposed to SOD1 muscles in
Wt-.SOD1 transplant animals (80–85 days before receiving
transplant of Wt muscle). However, only the latter group showed
MG motor terminal degeneration while MG innervation in the
former group was indistinguishable from normal. It is possible that
the 2–3 week difference in exposure time is a factor in determining
motorterminal degeneration.However,ifthe amount ofexposure to
potentially toxic muscle is a critical factor in determining degener-
ation, then one might reasonably expect to find that the unoperated
sides of Wt-.SOD1 transplant animals exhibit more extensive NMJ
degeneration than the transplanted sides. In these cases, the
unoperated sides were exposed to potentially toxic muscle for the
entire lifetime of the animals (140–145 d) whereas the transplanted
sides were exposed only for pre-transplant time intervals (80–85 d).
Yet, as Figure 4 demonstrates, both sides showed essentially identical
levels of denervation at 140–145 d. In the Wt-.SOD1 group, we
can not exclude that innervation of muscles that express mutant
protein during earlier life intervals (0–80 d) sets in motion degener-
ative mechanisms that progress despite later innervation of wildtype
muscle. However, our results do not provide clear support for the
idea that the amount of exposure to mutant SOD1 muscle is critical
for determining whether motor terminal degeneration occurs.
Selective regeneration of muscle fibers in transplanted muscles
provides another possible explanation for the success of wild-type
innervation of B6.SOD1 muscles. Although fiber number appears
to recover in transplants of normal muscle [25,26], we can not
exclude that transgenic muscle fibers that may possess specific
toxicity for motor terminals do not regenerate after transplantation.
If such transgenic fibers exist, however, then the basis of the toxicity
Figure 4. NMJ innervation status in muscle transplants is
determined by the host. Panel shows a plot of percentage of
innervated and of partially-innervated and denervated MG muscle fibers
observed in MG muscle transplants versus the same percentages from
contralateral control MG muscles. Symbols are defined by inset. Straight
line in plot has a unitary slope. Data from all study animals are included
in this plot. The association of innervation status between transplanted
and control muscles suggests mutual dependence on the properties of
the host.
doi:10.1371/journal.pone.0009802.g004
Table 1. Group means of innervations status for contralateral control and transplanted muscles.
Innervated Partial Dennervated
Donor/host Contralateral Transplant Contralateral Transplant Contralateral Transplant
B6.SOD1/WT 99619 3 621 615 610 602 61
WT/B6.SOD1 63686 4 610 15628 612 2 672 8 610
Values represents mean percentage 61 SEM. N=5 for all means.
doi:10.1371/journal.pone.0009802.t001
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B6.SOD1
G93A protein since fibers that did regenerate in transplants
but did not cause motor terminal degeneration expressed the
mutant protein. Other results suggest that B6.SOD1 motor neurons
that innervate fast type motor units are more susceptible to
degeneration in SOD1
G93A mice, an effect that could be based on
toxicity of fast type muscle fibers [6,10,21]. Such type-specific
selectivity is unlikely to be based upon intrinsic toxicity properties of
fastmuscle fibers since these muscle fibers in transplanted B6.SOD1
muscles were successfully re-innervated by wild-type motor neurons
in a manner similar to contralateral, control wild type muscles.
The results also show that NMJ innervation status in wild-type
muscles transplanted into B6.SOD1 mice is equivalent to the
contralateral control side. This equivalence could arise because the
transplants are initially completely reinnervated by B6.SOD1
motoneurons and subsequently become denervated, or because
reinnervation is incomplete. It seems improbable that in every
B6.SOD1 recipient, re-innervation failure in transplanted wild-
type muscle would be nearly identical to active denervation on the
control side. Since the majority of wild-type fibers were innervated
on average 2 months after transplantation, it seems more likely
that re-innervation of the wild-type transplant was fairly complete
initially and that denervation occurred subsequently. If confirmed
by sequential imaging, this would mean that B6.SOD1 motor
neurons can support re-innervation of transplanted muscles
initially but that degenerative changes eventually appear only
after the synapse has matured and experiences increased activity.
Terminal Schwann cells
Another issue addressed in the present study was the source of
terminal Schwann cells (TSCs) in transplants, and the results show
that in wild-type animals, the host provides TSCs located over
motor terminals in muscles transplanted 2 months earlier. This
indicates that adult TSCs, like muscle fibers, do not survive
transplantation. The ability of TSCs to survive may differ in
transplanted neonatal muscles where up to 50% of TSCs are
reported to be derived from the host [24]. Re-populating TSCs are
likely derived from host Schwann cells that invade the transplant
muscle along with host nerve fibers in a manner similar to original
innervation during embryonic development [27].
Since muscles transplanted from B6.SOD1 to wild-type animals
all showed complete reinnervation and normal endplates, it seems
reasonable to suppose that host-derived nerve terminal-TSC and
Schwann cell-motor axon combinations were present. It also
seems reasonable to infer that wild-type donor TSCs did not
survive when wild-type muscles are transplanted into B6.SOD1
animals and are likely to be replaced by TSCs derived from the
B6.SOD1 hosts. These ideas may have important implications for
the conditions needed for either preventing or enabling motor
terminal degeneration. Previously, Lino et al [2] showed that
expression of the mutant SOD1
G93A protein in neurons alone
(including motor neurons) was not sufficient to cause or greatly
attenuate the motor neuron disease phenotype. The results of the
present study show that expression of the mutant protein in muscle
is similarly not sufficient to produce degeneration of motor
terminals. However, when motor neuron-Schwann cell combina-
tions are present in wild-type muscles transplanted into B6.SOD1
mice and both cell types likely express the SOD1
G93A mutation,
nerve terminal degeneration proceeds in a manner indistinguish-
able from the contralateral, control side. Conversely, when the
motor neuron-Schwann cell combination does not express the
mutant SOD1
G93A protein, motor terminal degeneration does not
proceed despite the presence of muscle that does express the
mutant enzyme. Taken together, these results suggest that mutant
protein expression by both motor neurons and Schwann cells is at
least sufficient to enable motor terminal degeneration while
expression in either motor neuron or muscle alone is not. It is
possible that expression of mutant SOD1
G93A in TSCs and
myelinating Schwann cells alone or in combination with motor
neurons may be necessary for motor terminal degeneration.
Evidence has been reported previously that non-neuronal
supporting cells (glial cells) play an important role in mediating
Figure 5. Terminal Schwann cells in transplanted adult muscle are derived from the host. A. Low magnification view of a wild-type MG
muscle transplanted 2 months earlier into a transgenic mouse that expresses EGFP (green) under the direction of the S100 promoter. Endplate ACHRs
are stained with a2Btx (red). This panel illustrates the general finding that all endplate staining colocalized with EGFP. B. EGFP fluorescence was
absent at motor endplates in an MG muscle from an EGFP-expressing transgenic transplanted into a wild-type host (B1) but the same endplates
stained positively for S100 (green, B2), demonstrating that terminal Schwann cells were derived from the host. C. To exclude the possible survival of
wild-type TSCs after transplantation of wild-type muscle into the ECFP transgenic (C1), muscle sections were first labeled for S100 (C2) but all labeling
was found to colocalize with EGFP fluorescence (C3) providing further evidence that wild-type TSCs did not survive transplantation.
doi:10.1371/journal.pone.0009802.g005
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mutant mouse [3–5,10]. This evidence indicates that pathological
changes in motor neuron cell bodies are not cell autonomous. The
results of the present study extend these indications to include the
motor axon, motor terminal and Schwann cells. This raises the
interesting possibility that adverse relationships between glial cells
and motor neurons in the spinal cord may be replicated in the
periphery between motor terminals and TSCs. Since degeneration
of motor terminals and peripheral motor axons precedes motor
neuron cell death [6–8], adverse interactions between TSCs and
motor terminals or between axons and myelinating cells could be
of direct importance for determining loss of motor unit function in
B6.SOD1 mice and conceivably trigger more widespread motor
neuron degeneration. In normal animals, TSCs have important
relationships with motor terminals that include the ability to
induce sprouting [28] and mechanisms that influence synaptic
release [29]. Evidence is also available that ablation of TSCs is
associated with motor terminal degeneration following a delay
[30]. These observations indicate the existence of crucial
relationships between the TSC and the motor terminal that may
turn out to be of importance for understanding how degenerative
changes begin in the B6.SOD1 mouse and perhaps in human
victims as well.
Methods
Animals
Strain background can have a powerful effect on phenotypic
expression [31]. The background strain of mice used for many
studies of the human SOD1 mutation is a B6SJL mixed hybrid
strain [B6SJL-TgN(SOD1-G93A)1GUR] maintained by crossing
transgene-positive male mice with B6SJL F1 hybrid females. This
breeding strategy produces animals that are not genetically
identical and thus random litter effects may significantly modify
disease processes. To avoid this possible variation, we used an
inbred congenic strain of mice B6.Cg-Tg(SOD1-G93A)1Gur/J
carrying the G93A mutant form of the human SOD1 transgene
[1]. In this paper, these mice arel referred to as B6.SOD1. These
mice exhibit early changes in motor performance (ca. 50 days) but
survive about 1 month longer than B6SJL SOD1 transgenic mice
[32]. Congenic B6.SOD1G93A and C57BL/6J mice are mutually
compatible donors because congenic mice have been backcrossed
to C57BL/6J for 15 generations and are essentially genetically
identical. Thus, immunosuppresive therapy was not performed in
the present study.
In order to facilitate imaging, C57BL/6J (B6).Cg-Tg(Thy1-
YFP)16Jrs/J mice (hereafter YFP16) [18] were crossed to
B6.SOD1 mice to create double transgenics on the B6
background. These mice and YFP16 wildtypes were used for all
transplant experiments involving the SOD1 mutation. For
experiments involving terminal Schwann cell (TSC) fate after
transplantation, B6.D2-Tg(S100B-EGFP)1Wjt/J mice were used
(hereafter B6.EGFP). These mice express enhanced green
fluorescent protein (EGFP) under the direction of the human
S100 calcium-binding protein promoter [16] to produce fluores-
cent Schwann cells. All animals were acquired from The Jackson
Laboratory (www.jax.org, Bar Harbor, ME).
Transplant surgery
All transplants were performed under general anesthesia
(ketamine 24 mg, xylazine 1.3 mg per ml)) For all transplant
experiments, the right medial gastrocnemius (MG) muscle was
carefully exposed and the tendons of origin and insertion and the
MG nerve were severed. The MG muscle was then carefully
separated from the lateral gastrocnemius muscle by cutting along
the midline through the tendon shared by these two muscles. The
excised MG was then placed into the bed created by the removal
of MG muscle from the recipients. The tendons of origin and
insertion of the transplanted MG were attached with a 10-0 suture
to the remnants of tendons of the recipient MG muscle. The
proximal stump of cut MG nerve of the recipient was placed in
close proximity to the nerve stump of the MG transplant. The
crural fasciae and skin incisions were closed using 6-0 monofila-
ment suture. The animals were then returned to their cages for
recovery and 2 full days of post-operative analgesics. Food and
water were administered ad lib following recovery and animals
were allowed to move freely in their cages.
Muscle transplantations were performed in B6.SOD1 animals
aged 80–85 days. This age occurs after hindlimb gait disturbances
can first be detected but well before readily apparent clinical
symptoms appear [32]. Muscles were recovered from animals aged
140–145 days at which time symptoms begin to appear on
average. All experiments were carried out in accordance with the
Institutional Animal Care and Use Committee of Emory
University.
Western blotting
Muscles were homogenized on dry ice with a mortar and pestle
and reconstituted at 10% (wt/vol) in RIPA buffer. Protein
concentrations were determined by spectrophotometry via a
BCA protein assay kit, and 20 ug samples of protein were
fractionated by electrophoresis in 5% stacking and 15% resolving
acrylamide gels and transferred to PVDF filters (Immobilon-P
Transfer Membrane). Filters were then incubated with the affinity-
purified antibody at 1:500 dilution (Chemicon International
#AB5482 Rabbit Anti-SOD1 mouse specific and #AB5480
Rabbit Anti-SOD1 human specific). Control and mutant extrac-
tions were loaded and run on the same gel.
Immunolabeling
MG muscles were recovered from each limb and placed into
4% paraformaldehyde for 1 hr. Muscles were washed in a 0.1 M
phosphate buffered solution (PBS) and incubated at 4uC overnight
in PBS containing 20% sucrose for cryoprotection. Sections
(50 mm thickness) were obtained using a Cyrostat (Leica). Motor
endplate acetylcholine receptors (AChRs) were labeled with
rhodamine conjugated a-bungarotoxin (Molecular Probes). Axons
and motor nerve terminals were labeled with a mouse monoclonal
antibody against the phosphorylated heavy fragment of neurofil-
ament protein (SMI31, 1:400, Sternberger Monoclonal). Labeling
was visualized using fluorescein-conjugated secondary antibody
(1:100, Jackson Immunoresearch Laboratories). Synaptic vesicles
were labeled using a rabbit polyclonal antibody directed at
synaptophysin (1:100, Santa Cruz Biotechnology), and terminal
Schwann cells (TSC) were labeled with a rabbit polyclonal
antibody against S100 Ca
2+-binding protein (Dako). Both synaptic
vesicles and terminal Schwann cells were visualized using an
AMCA-conjugated secondary antibody (1:100, Jackson Immunor-
esearch Laboratories). Muscle fibers were labeled with a
monoclonal antibody that recognizes the neonatal and all of the
adult fast MyHC isoforms (MY-32, Sigma). Labeling was
visualized with a rhodamine-conjugated secondary antibody
(1:100, Jackson Immunoresearch Laboratories).
Imaging
Z-axis stacks of images of NMJs were obtained at sequential
focal planes (0.5 mm separation) using an upright microscope
equipped with a motorized stage (Leica). Stacks were deconvolved
Motor Terminal Degeneration
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9802using a commercially available inverse filter algorithm (ImagePro).
Illustrated images are flat plane projections obtained by summing
deconvolved image stacks. Analysis consisted of evaluating NMJ
innervation status for the extent to which presynaptic labeling
overlaid postsynaptic labeling for AChRs in superimposed images.
Three categories of innervation status were used as described
previously [33]. Fibers were considered fully innervated if
presynaptic labeling for synaptic vesicles completely covered the
entire endplate area labeled for AChRs when images of vesicle and
AChR labeling were superimposed. Fibers were considered
partially innervated or denervated, if only parts or none,
respectively, of the endplate labeled for ACh receptors area was
occupied by the synaptic vesicles staining. For analysis, randomly
selected fields of NMJs were first located at low magification.
Then, all the NMJs in each field were categorized as described
above.
Statistics
Statistical comparisons of innervation status data were made
between the transplanted (left) and the contralateral control (right)
MG muscles. For analysis, two-way contingency tables (innerva-
tion status vs. muscle source (transplant or control) were used to
determine whether statistically significant differences existed in the
percentage of innervated and denervated endplates observed in
the transplanted and control MG. To enable use of two-way
tables, counts of partially innervated and denervated endplates
were merged into one category characterized as not fully
innervated. The Mantel-Haenszel test for 2 x 2 contingency tables
to test for association between innervation and muscle source (side)
in individual animals while controlling for possible effects of
different animals. All analysis was performed with commercially
available software (Systat Inc). Mean values are presented 61
SEM.
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